| Name | Title | Contact Details |
|---|---|---|
Amos Oveson |
Director of Sales and Customer Service | Profile |
Nate Randall |
VP, Supply Chain and Logistics | Profile |
Vince Kreipke |
Director Of Product Development | Profile |
Amelie Liger |
Director of Human Resources | Profile |
Providence Health & Services is a non-profit, Catholic health care system operating multiple hospitals across eight states, with headquarters in Renton, Washington.
Nicka & Associates, Inc is a Plano, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Shamrock Medical Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relievant Medsystems, Inc., a privately held medical device company pioneering the INTRACEPT therapy of nerve ablation within vertebral bodies for the treatment of chronic low back pain (CLBP). The INTRACEPT Intraosseous Nerve Ablation System is a patent-protected, minimally invasive, implant-free therapy that utilizes radiofrequency energy delivered into the vertebral body of the spine to ablate the Basivertebral Nerve (BVN). This nerve, characterized in peer-reviewed literature reporting studies of pain signal transmission and in preclinical and clinical evaluations, is a significant contributor in the transduction of pain arising from degeneration of the vertebral bodies associated with CLBP. The INTRACEPT Intraosseous Nerve Ablation System leverages proprietary instruments and methods to disable this nerve.
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla`s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world`s first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics.